Loading...

Stay current with insights from our analysts and industry updates.  Subscribe to one of our HealthCheck24 newsletters to receive regular weekly insights by email. We also offer customised newsletters to keep your management, sales and marketing teams fully informed - contact us to find out more.

AMA, insurers dig in for private health battle in Australia

Image

21-Dec-15 Australia's doctors lobby has warned the government not to allow health funds to price insurance based on factors such as age and lifestyle, while attacking "junk" policies that don't cover common procedures. Government budgets are under strain and surging costs have put pressure on premiums, prompting a federal review into private insurance and other reviews of the health system. [image: Andrew Meares / The Age]

Read More

Japanese players slow to see that data drives latest equipment trend

Image

15-Dec-15 At the recent RSNA exhibition in Chicago, GE proposed a system for information sharing across multiple settings, and Siemens devoted a big chunk of its space to the use of data, while Japanese players used the event to showcase more traditional technology. Finding ways to use data more effectively is assuming growing importance, but Japanese makers appear less interested in following this trend. [image: Nikkei Asian Review]

Read More

Parkway plans big India push

Image

16-Dec-15 Singapore-based Parkway Pantai, one of Asia's largest healthcare providers, is planning huge healthcare capacities in India, challenging leaders like Apollo and Fortis. Parkway, owned by the Malaysian sovereign fund-backed IHH Healthcare, is planning to add up to 5,000 beds in the next two years, half of this in India, said Dr Tan See Leng, managing director of Parkway and IHH. [image: Business Today]

Read More

AstraZeneca investing USD800 mn to go local in China

Image

16-Dec-15 AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than USD800 mn in the country over the next 10 years. The British drugmaker's decision to step up investment, notably through a strategic alliance with WuXi AppTec, chimes with Beijing's desire to see more treatments made in China. [image: China Daily]

Read More
Share